Published in Lab Business Week, September 19th, 2004
"We are pleased with the progress we made during the second quarter as we continue to advance the clinical development of our lead Hepatitis C and Hepatitis B programs," said Kleanthis G. Xanthopoulos, PhD, Anadys' president and CEO.
"Meanwhile, we continue to harvest additional promising drug candidates utilizing our integrated drug discovery and development platform, while leveraging these capabilities in discovery collaborations with pharmaceutical and biotechnology companies such as Roche and Daiichi.
"We hope to build on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.